var data={"title":"Clofazimine (United States: Available via National Hansenâ€™s Disease Program and FDA investigational drug [IND] protocol only): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5923?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Drug information&quot;</a> and <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">see &quot;Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46490723\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46977608\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">see &quot;Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leprosy, lepromatous (multibacillary):</b> Limited data available: <b>Note:</b> Use in combination with dapsone and rifampin; dosing interval due to limitations with available dosage forms not pharmacokinetics-related; capsules should not be opened, lowest available strength is 50 mg; patients must be able to swallow capsule whole.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen Disease Program (NHDP [HRSA 2016]): Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;50 kg: Oral: 2 mg/kg/dose every other day for 24 months</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg: Oral: 1 mg/kg/dose once daily for 24 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization (WHO):</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Children &lt;10 years: Oral: 50 mg twice weekly and 100 mg once a month (WHO 2010) or 1 mg/kg every other day for 12 months (WHO 2012)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Children &ge;10 years and Adolescents &lt;15 years: Oral: 50 mg once every other day and 150 mg once a month (directly observed) for 12 months (WHO 2010; WHO 2012)</p>\n    <p style=\"text-indent:-4em;margin-left:10em;\">Adolescents &ge;15 years: 50 mg once daily and 300 mg once a month (directly observed) for 12 months (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erythema nodosum leprosum (Type 2 lepra reaction):</b> Limited data available (WHO 2012): Children and Adolescents: Oral: 100 mg three times daily; full response typically requires 4 to 6 weeks of therapy. <b>Note:</b> Clofazimine therapy recommended for patients with poor response to corticosteroids, or for whom corticosteroids are not a therapeutic option.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Leprosy, lepromatous (multibacillary):</b> Oral:</p>\n    <p style=\"text-indent:-6em;margin-left:8em;\">National Hansen Disease Program: 50 mg once daily, in combination with dapsone and rifampin, for 24 months (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-6em;margin-left:8em;\">World Health Organization: 50 mg once daily and 300 mg once a month (directly observed), in combination with dapsone and rifampin, for 12 months (WHO 2012<b>)</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22785794\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral: 50 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443770\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;\">Clofazimine is not commercially available in the US; it is distributed through the National Hansen&rsquo;s Disease Program (NHDP). NHDP holds the Investigational New Drug (IND) application for treatment of leprosy in the United States. In order for physicians to obtain clofazimine, they have to register as an investigator under the NHDP IND. This requires submitting a curriculum vitae and a signed FDA form 1572 to the NHDP. For further information, or to request investigator status, please call the NHDP at 1-800-642-2477. For additional information: <a target=\"_blank\" href=\"http://www.hrsa.gov/hansensdisease/index.html&amp;token=Avgmwaq5aLk79THpXqFRKBZwKXlzl6U4GxRPr43+7igzxd9ZUflk3IWwLfPoAFpQXkC8NQOlbPB6S1pdeEB7kg==&amp;TOPIC_ID=109477\" target=\"_blank\">http://www.hrsa.gov/hansensdisease/index.html</a>.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For use of clofazimine in medical conditions other than leprosy, physicians must contact the Food and Drug Administration (FDA) to submit a request for a single patient IND. Physicians should contact the FDA Division of Special Pathogen and Immunologic Drug Products (HFD-590) at 301-796-1600. Upon approval of the single patient IND, the FDA requests NHDP to distribute clofazimine directly to the prescriber.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">International: No longer available commercially. In nations where a national leprosy elimination program exists, the Ministries of Health make an official request to the World Health Organization (WHO) for clofazimine. In nations where no such program exists, doctors or pharmacists from individual institutions contact the WHO with a request. A request can be made to the WHO via a letter, fax, or email to verify that the drug will be used to treat a severe ENL reaction due to leprosy and how many patients need the drug. If these conditions are met, a free supply of clofazimine will then be made available. For treatment of MDR-TB, the WHO handles decisions regarding distribution on an individual case-by-case basis. For additional information: http://www.who.int/lep/mdt/clofazimine/en/. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46490726\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with meals; capsules must be swallowed whole and should not be opened.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443859\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store below 30&ordm;C (86&ordm;F). Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46490724\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of lepromatous (multibacillary) leprosy, in combination with other agents in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46440424\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Clofazimine may be confused with cloZAPine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49165746\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Discoloration of sweat, ichthyosis, pruritus, skin pigmentation (brownish-black), skin rash, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, fecal discoloration, gastrointestinal disease, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Increased erythrocyte sedimentation rate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Burning sensation of eyes, corneal changes (pigmentation), eye irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Discoloration of sputum</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acneiform eruption, anemia, anorexia, cheilosis, constipation, cystitis, depression, dizziness, drowsiness, edema, enteritis, eosinophilia, erythroderma, fatigue, gastroenteritis, gastrointestinal hemorrhage, headache, hepatitis, hepatomegaly, hypokalemia, increased serum albumin, increased serum AST, increased serum bilirubin, intestinal obstruction, jaundice, lymphadenopathy, maculopathy (FDA Safety Alert, Nov. 11, 2016), neuralgia, ostealgia, phototoxicity, prolonged QT Interval on ECG (FDA Safety Alert, Nov. 11, 2016), skin discoloration (FDA Safety Alert, Nov. 11, 2016), splenic infarction, taste disorder, thromboembolism, pain (vascular), vision loss, weight loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49366479\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to clofazimine or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443856\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Cases of torsades de pointes (TdP) with QT prolongation have been reported in patients taking &gt; 100 mg/day or in combination with other QT prolonging drugs. If TdP or QT prolongation occurs, patient must remain under medical surveillance while monitoring ECGs and cardiac rhythm.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic effects: May cause photosensitivity (Legendre 2012). Use skin protection and avoid prolonged exposure to sunlight; do not use tanning equipment. May cause skin dryness, pruritus, and ichthyosis; oil-based skin preparations may relieve symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: May accumulate as crystals in organs including intestinal mucosa, spleen and liver. Intestinal mucosa deposition may lead to obstruction that may require exploratory laparotomies in some patients. Splenic infarction and GI bleeding (some fatal) have also been reported. May be dose related; dosages &gt;100 mg/day should be used for the shortest duration possible (&lt;3 months) and only under close supervision. If patient complains of abdominal pain (colicky or burning), nausea, vomiting, or diarrhea, initiate clinical investigations and decrease dose, increase dosing interval, or discontinue therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin and body fluid discoloration: Discoloration of the skin (red to brownish-black) or conjunctivae, lacrimal fluid, sweat, sputum, urine and feces may occur in 75% to 100% of patients. Skin discoloration is reversible after treatment discontinuation; however, disappearance of discoloration may take several months to years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull;  Suicidal ideation: Suicide has been reported (rare); thought to be related to depression due to skin discoloration. Advise patients about potential for skin discoloration and monitor for suicidal ideation during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Depression: Use with caution in patients with a history of depression; skin discoloration caused by clofazimine may result in depression. Advise patients about potential for skin discoloration and monitor for depressive symptoms during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Use with caution in patients with gastrointestinal disorders, including abdominal pain and diarrhea.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lenses: Remove contact lenses during therapy; staining may occur (Legendre 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283930\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46283927\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109477&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: Clofazimine may enhance the QTc-prolonging effect of Bedaquiline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443943\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Clofazimine crosses the placenta. Infants born to women who have received clofazimine during pregnancy had deeply pigmented skin at birth with gradual fading over 1 year (Holdiness 1989). Because leprosy is exacerbated during pregnancy, the WHO recommends that standard treatment regimens should be continued during pregnancy (WHO 1998).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46490727\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">GI symptoms (eg, abdominal pain, nausea, vomiting, diarrhea); skin for discoloration; periodically monitor liver function tests and serum creatinine (WHO 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443860\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Exact mechanism unknown; antibacterial activity may be due to binding to DNA of <i>Mycobacterium leprae</i>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46443862\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Variable and incomplete (45% to 62%); may be increased when administered with food (Legendre 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Highly lipophilic; deposits primarily in fatty tissues and cells of reticuloendothelial system</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: &ge;70 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22786938\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Clofozine (IN);</li>\n      <li>Fazim (IN);</li>\n      <li>Feza (IN);</li>\n      <li>Hansepran (IN);</li>\n      <li>Lamcoin (TH);</li>\n      <li>Lampren (ES, JP, NL);</li>\n      <li>Lamprene (AU, CH, CZ, EG, FR, GR, HK, IR, MY, NZ, SA);</li>\n      <li>Lapren (KR);</li>\n      <li>MB-Combi (SA);</li>\n      <li>Neozimina (BR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al,<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children,</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freerksen E, Seydel JK. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. <i>Arzneimittelforschung</i>. 1992;42(10):1243-5. Review.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/1472145/pubmed\" target=\"_blank\" id=\"1472145\">1472145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens.  http://www.hansensdisease/diagnosis/recommendedtreatment.html. Accessed on March 31, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. <i>Clin Pharmacokinet</i>. 1989;16(2):74-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/2656045/pubmed\" target=\"_blank\" id=\"2656045\">2656045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; July 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Legendre DP, Muzny CA, Swiatlo E. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. <i>Pharmacotherapy</i>. 2012;32(1):27-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/22392826/pubmed\" target=\"_blank\" id=\"22392826\">22392826</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      WHO Model Formulary for Children, 2010. Available at http://apps.who.int/medicinedocs/en/m/abstract/Js17151e/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. Drugs Used in Leprosy. http://apps.who.int/medicinedocs/pdf/h2988e/h2988e.pdf. Accessed April 6, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61, 1 p following 61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-pediatric-drug-information/abstract-text/22970604/pubmed\" target=\"_blank\" id=\"22970604\">22970604</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109477 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F46490723\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F46977608\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F22785794\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F46443770\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F46490726\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F46443859\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F46490724\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F46440424\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F49165746\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F49366479\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F46443856\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46283930\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46283927\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F46443943\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F46490727\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F46443860\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F46443862\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F22786938\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/109477|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Drug information</a></li><li><a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-patient-drug-information\" class=\"drug drug_patient\">Clofazimine (United States: Available via National Hansen&rsquo;s Disease Program and FDA investigational drug [IND] protocol only): Patient drug information</a></li></ul></div></div>","javascript":null}